Depression Relief ASAP

A Global Health Crisis

In 2022, nearly 23% of U.S. adults—roughly 60 million people—reported experiencing mental health challenges within the past year. Tragically, 49,500 lives were lost to suicide that year, and since then, the nation’s suicide rate has continued to rise.

Many believe psychedelics could transform mental healthcare, especially for those in crisis. However, the journey from today’s landscape to accessible, effective psychedelic treatments is a complex one.

For psychedelic therapies to reach those in need, a careful balance among diverse stakeholders—healthcare providers, insurers, the VA, the FDA, the DEA, and advocates from the global psychedelic community—is essential.

One of the biggest challenges is reaching a consensus on when, where, and how these substances can be legally administered. What treatment models will be available for which substance? Who qualifies? And under what circumstances?

In today’s discussion, we’ll dive into psychedelic treatment models, at-home microdosing, and a groundbreaking protocol fueling an exciting clinical trial—one that might offer new hope for treating depression in adults.

Psychedelic Treatment Models

Psychedelics in healthcare are generally accessed by two primary approaches, each offering unique benefits and limitations:​

Psychedelic Assisted Therapy: The patient takes the psychedelic under the supervision of a licensed professional and remains in a controlled setting until the experience concludes.

• Strength: Continuous professional guidance ensures safety and support throughout the session.

• Weakness: High cost and resource-intensive, making it difficult to scale for widespread use.

At-Home Microdosing: The patient receives a prescription and administers small doses of the psychedelic at home, following a specific protocol.

• Strength: More affordable and scalable, allowing broader access without the need for clinical supervision.

• Weakness: Lacks professional oversight, leaving patients to independently manage potential side effects and track their progress.

At Microdosing.com, we’re committed to making new, accessible healthcare solutions available to those who need them without delay.  We support both models because offering diverse options to meet patients’ unique needs will achieve the best outcomes for the most people.

Take-Home LSD: A Game Changer for Microdosing 💊✨

The Breakthrough

MindBio Therapeutics is making headlines with MB22001—the first-ever LSD microdose designed and approved for safe, at-home use. This advancement promises to be a game-changer in mental health treatment and access.

A Win for the Psychedelic Community

This study is rooted in the well-known Fadiman Microdosing Protocol, widely regarded as the gold standard for LSD microdosers worldwide. By following this protocol, those curious about microdosing’s potential benefits can explore it from home, even as FDA approval for MB22001 is still in progress.

Why Precision Matters

One of the most exciting aspects of MB22001 is that it’s pharmaceutically measured. Until now, microdosing LSD has often involved DIY methods—diluting liquid LSD or cutting blotter—which can result in imprecise dosing and inconsistent experiences. This unreliability can be especially challenging for those already struggling with mental health. A precise, pharmacy-measured LSD microdose means a more consistent, reliable experience, offering new hope for those seeking stability and relief.

What’s Next for Microdosing

MB22001 has the potential to pave the way for safe, consistent, and impactful at-home microdosing options. This marks a major step forward for psychedelic-assisted wellness, bringing the benefits of microdosing closer to those in need.

MindBio's Road Map:

• Completed: Phase 2a trial for Major Depressive Disorder (MDD): 72% of participants had fewer depression symptoms, and 58% went into full remission.

• Ongoing: Phase 2B trials for MDD and cancer patients: Looking at how MB22001 can help with depression and stress in cancer patients.

• Upcoming: trial for PMS and PMDD: Testing whether microdosing can help with the emotional symptoms of PMS and PMDD.

Dr. James Fadiman’s Microdosing Protocol

Dr. James Fadiman, known as the “godfather of microdosing,” pioneered one of the first widely-used microdosing protocols. His approach is all about small, consistent doses that offer subtle, mood-enhancing effects—without the full psychedelic experience.

The Fadiman Protocol

• Dosage: 5-10 micrograms of LSD

• Schedule: Microdose every three days

• Self-Monitoring: Track experiences in a journal to capture mood shifts and make adjustments

This simple, structured approach has helped countless people enhance their well-being, boost creativity, and improve focus.

A New Era of Mental Health Care

LSD microdosing is paving the way toward a future where effective, fast-acting mental health treatments are more accessible, affordable, and empowering.

Let’s keep an open mind as we explore this innovative approach to mental health care—there’s so much promise on the horizon!

This is a reminder to check on your buds—give them a call or a text and tell them you're thinking of them. It could make all the difference.

_{In Crisis? If you’re having thoughts of self-harm please call 988 or visit 988Lifeline.org. If you’re experiencing a difficult trip, or need help integrating one, consider contacting Fireside Project by calling or texting 62-FIRESIDE or visit firesideproject.org.}